Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 633824 | ISIN: SE0000936478 | Ticker-Symbol: IJU
Tradegate
24.01.25
09:01 Uhr
2,623 Euro
+0,027
+1,04 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
INTRUM AB Chart 1 Jahr
5-Tage-Chart
INTRUM AB 5-Tage-Chart
RealtimeGeldBriefZeit
2,6482,67111:02
2,6482,67211:02
GlobeNewswire (Europe)
213 Leser
Artikel bewerten:
(1)

Intrum: Intrum AB - Interim results July-September 2024

Finanznachrichten News

Intrum delivers steady financial performance in third quarter and makes significant progress towards key financial targets and comprehensive recapitalisation

  • Continued expansion of Servicing margin and stable collections in Investing business, despite cyclically slow nature of quarter
  • Progress on capital light strategy with five transactions agreed as part of the investment partnership with Cerberus
  • Cost reduction programme on target and delivering meaningful impact
  • Significant progress on recapitalisation having achieved overwhelming support from creditors; now focused on implementation of transaction

Andrés Rubio, President & CEO of Intrum AB said:

"I am pleased with the progress we have made this quarter in both the Servicing and Investment businesses and our cost reduction initiatives are delivering. We also received overwhelming support from creditors on our recapitalisation transaction, which will ensure we have a capital structure which is aligned with our long-term business plan. We remain committed to our capital-light strategy which enables us to scale our investment activity without increasing our debt, while benefitting from long term servicing and portfolio management revenue. We continue to be focused on deleveraging, further strengthening our market-leading position and achieving our financial targets for 2026."

Key financial highlights, July-September 2024 (July-September 2023)

  • Servicing adjusted EBIT increased by 45% vs. Q3 2023
  • Servicing adjusted EBIT margin increased to 18% (+6% vs. Q3 of the previous year)
  • External servicing income decreased 4%
  • Positive Q3 organic growth in Servicing in Northern and Middle Europe of 4% and 3%, respectively
  • Collection performance in Investing during the quarter of 98% and 106% vs. active and original forecast, respectively
  • Investing cash income and cash EBITDA decreased 5% and 17% respectively vs. Q3 2023 primarily driven by lower investment pace, a natural consequence of the move to a capital light strategy
  • New portfolio investments of SEK 311 M (SEK 531 M) at IRR of 20% (18%)
  • Investing book-value stood at SEK 25.5 bn (38.8)
  • Available liquidity at the end of the quarter was SEK 3.8 bn (8.9), driven by significant debt reduction

Third quarter figures in summary

  • Income down 5% vs. Q3 2023 driven by decreases in both Investing and Servicing segments
  • Adjusted EBIT for the quarter decreased to SEK 951 M vs. SEK 1,004 M in Q3 2023
  • Adjusted costs in the third quarter amounted to SEK 3,279 M, an 8% decrease compared to SEK 3,549 M in the third quarter last year
  • Realised cost savings of SEK 1.1 bn by the end of Q3 2024 and adj. cost-income ratio decreased 2% vs. Q3 2023
  • Leverage ratio of 4.2x (4.4x). Up 0.3x vs. Q2 2024, driven by a reduction in RTM cash EBITDA following completion of the portfolio investment back-book sale
  • Progress on several strategic initiatives including:
    • Meaningful progress on recapitalisation
    • Five transactions agreed as part of its investment partnership with Cerberus
    • Ambitious roll-out plan for Ophelos with initial deployment in Spain

Presentation of the interim report

Andrés Rubio, President & CEO, and Johan Åkerblom, CFO, will present the results and answer questions in a webcast with teleconference at 9:00 a.m. CET. The conference will be held in English.

If you wish to participate via webcast, please use this link. Via the webcast you are able to ask questions in writing.

To participate via teleconference, please use this link. After registration you will be provided phone numbers and a conference ID to access the conference. Via the teleconference you can ask questions verbally.

For further information, please contact:

Investor Relations
Anders Bengtsson, Investor Relations Manager
ir@intrum.com

Förfrågningar från media
Kristin Andersson, External Communications Director
+46 70 585 78 18
kristin.andersson@intrum.com

About Intrum

Intrum is the industry-leading provider of Credit Management Services with a presence in 20 markets in Europe. By helping companies to get paid and supporting people with their late payments, Intrum leads the way to a sound economy and plays a critical role in society at large. Intrum has circa 10,000 dedicated professionals who serve around 80,000 companies across Europe. In 2023, income amounted to SEK 20.0 billion. Intrum is headquartered in Stockholm, Sweden and publicly listed on the Nasdaq Stockholm exchange. For more information, please visit www.intrum.com.

This information is information that Intrum is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-23 07:00 CEST.

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.